Incb099280
Microsatellite Instability - High (MSI-H)
Incyte CorporationPhase 1Active
C
32/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 17/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Microsatellite Instability - High (MSI-H) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 2 | B |
Cyclophosphamide ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 2 | CCC |
Dpx-Survivac ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 2 | CCC |
Ipilimumab Incyte Corporation | Phase 1 | CC |
Nivolumab National Cancer Institute (NCI) | Phase 1 | CC |
Ipilimumab Incyte Corporation | Phase 1 | CC |
Incb099280 Incyte Corporation | Phase 1 | NR |
Same molecule, other indications
Incb099280 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →